These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 34794)

  • 41. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation.
    Auletta JJ; Devecchio JL; Ferrara JL; Heinzel FP
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):834-47. PubMed ID: 15570252
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow transplantation.
    Santos GW
    Adv Intern Med; 1979; 24():157-82. PubMed ID: 34319
    [No Abstract]   [Full Text] [Related]  

  • 44. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Graft-versus-leukemia following bone marrow transplantation.
    Butturini A; Bortin MM; Gale RP
    Bone Marrow Transplant; 1987 Oct; 2(3):233-42. PubMed ID: 3332173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of the treatment of parental cells in vitro with anti-T antibody on bone marrow transplantation in F1 hybrid mice.
    Hrubá A; Paluska E; Fricová V; Fiala J
    Folia Biol (Praha); 1980; 26(5):338-50. PubMed ID: 7002637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of natural killer cells in resistance to allogeneic and parental hybrid resistance.
    Waterfall M; Rayfield LS; Brent L
    Transplantation; 1987 Feb; 43(2):312-4. PubMed ID: 3544391
    [No Abstract]   [Full Text] [Related]  

  • 48. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies.
    Barrett AJ; Malkovska V
    Br J Haematol; 1996 Jun; 93(4):754-61. PubMed ID: 8703800
    [No Abstract]   [Full Text] [Related]  

  • 50. Strategies to enhance the graft-versus-malignancy effect in allogeneic transplants.
    Barrett JA
    Ann N Y Acad Sci; 1995 Dec; 770():203-12. PubMed ID: 8597361
    [No Abstract]   [Full Text] [Related]  

  • 51. Bone marrow transplantation in malignancy.
    Santos GW; Tutschka PJ; Elfenbein GJ
    Curr Probl Cancer; 1979 Dec; 4(6):3-22. PubMed ID: 42511
    [No Abstract]   [Full Text] [Related]  

  • 52. Natural killer cells in bone marrow transplantation.
    Lopez C; Kirkpatrick D; Livnat S; Storb R
    Lancet; 1980 Nov; 2(8202):1025. PubMed ID: 6107647
    [No Abstract]   [Full Text] [Related]  

  • 53. Bone marrow transplants in leukemia patients in remission.
    Fefer A
    CA Cancer J Clin; 1980; 30(1):45-52. PubMed ID: 6766350
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and theoretical implications of experimental bone marrow transplantation.
    Vitale B; Boranić M
    Br J Haematol; 1979 May; 42(1):1-7. PubMed ID: 37883
    [No Abstract]   [Full Text] [Related]  

  • 55. Antigen-specific lymphocyte therapies.
    Molldrem JJ
    Cytotherapy; 2002; 4(4):315-6. PubMed ID: 12396830
    [No Abstract]   [Full Text] [Related]  

  • 56. Graft-versus-host disease: immunobiological aspects.
    Tutschka PJ
    Haematol Blood Transfus; 1983; 28():97-101. PubMed ID: 6345301
    [No Abstract]   [Full Text] [Related]  

  • 57. Serological inhibition of graft versus host disease: recent results in 28 patients with leukemia.
    Rodt H; Thierfelder S; Bender-Götze C; Dopfer R; Haas FJ; Janka G; Kolb HJ; Link H; Netzel B; Niethammer D; Schüch K; Wilms K
    Haematol Blood Transfus; 1983; 28():92-6. PubMed ID: 6345300
    [No Abstract]   [Full Text] [Related]  

  • 58. Peripheral NK-cell activity after bone-marrow allograft.
    Tursz T; Dokhelar MC; Gluckman E
    Lancet; 1980 Feb; 1(8164):375. PubMed ID: 6101835
    [No Abstract]   [Full Text] [Related]  

  • 59. Anomalous killer cells: thymus cell dependency, precursor frequency, and response to immunosuppressive therapy.
    Merluzzi VJ; Kenney RE; Last-Barney K; O'Reilly RJ; Faanes RB
    Clin Immunol Immunopathol; 1982 Jul; 24(1):83-92. PubMed ID: 7049474
    [No Abstract]   [Full Text] [Related]  

  • 60. Lymphocyte physiology and function.
    Caldwell CW; Burningham RA
    Mil Med; 1975 Dec; 140(12):846-52. PubMed ID: 640
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.